Recent advances in the treatment of gynecologic cancers are promising, and education is needed to ensure that both oncology and primary care clinicians, including OB/GYNs, have a thorough knowledge of biomarkers, current and emerging therapies, and how the latest clinical …
Recent advances in the treatment of gynecologic cancers are promising, and education is needed to ensure that both oncology and primary care clinicians, including OB/GYNs, have a thorough knowledge of biomarkers, current and emerging therapies, and how the latest clinical …
Immune checkpoint inhibitors (ICIs), PARP inhibitors, VEGF inhibitors, kinase inhibitors, and chemotherapy are all being used in various combinations for the treatment of endometrial and ovarian cancers. As these new combinations seek to further improve and enhance the efficacy of …
Clinicians treating patients with T2D need to know how to choose and optimally use incretin therapies that have activity against common comorbidities in T2D, including obesity and CVD. Over the past decade there have been several new classes of drugs …
The emerging class of amyloid-targeting therapies (ATTs) are at the forefront of innovative approaches that promise to alter the course of Alzheimer’s disease (AD). However, the translation of these scientific advancements into clinical practice necessitates a well-informed clinical workforce adept …
Alzheimer’s disease (AD) presents a growing challenge in contemporary health care, with escalating prevalence and a significant burden imposed on patients, families, and health care systems globally. Early and accurate diagnosis of AD is essential for effective support and treatment. …
